Integrating biopharmaceutics risk assessment and in vivo absorption model in formulation development of BCS class I drug using the QbD approach.

MLA

Charoo, Naseem A., et al. “Integrating Biopharmaceutics Risk Assessment and in Vivo Absorption Model in Formulation Development of BCS Class I Drug Using the QbD Approach.” Drug Development & Industrial Pharmacy, vol. 43, no. 4, Apr. 2017, pp. 668–77. EBSCOhost, https://doi.org/10.1080/03639045.2016.1278013.

APA

Charoo, N. A., Cristofoletti, R., & Kim, S. K. (2017). Integrating biopharmaceutics risk assessment and in vivo absorption model in formulation development of BCS class I drug using the QbD approach. Drug Development & Industrial Pharmacy, 43(4), 668–677. https://doi.org/10.1080/03639045.2016.1278013

Chicago

Charoo, Naseem A., Rodrigo Cristofoletti, and Sun K. Kim. 2017. “Integrating Biopharmaceutics Risk Assessment and in Vivo Absorption Model in Formulation Development of BCS Class I Drug Using the QbD Approach.” Drug Development & Industrial Pharmacy 43 (4): 668–77. doi:10.1080/03639045.2016.1278013.